ClinicalTrials.gg
RecruitingNCT07259928NEXUSUpdated Dec 2, 2025

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion

A Phase 2 interventional study of ANXV in Non-Proliferative Diabetic Retinopathy and Retinal Vein Occlusion, sponsored by Annexin Pharmaceuticals AB. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Annexin Pharmaceuticals AB · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Retinal Vein Occlusion with a site in United Kingdom — 2 open to participants now, 3 under way, none of them phase 3. Retinal Vein Occlusion · United Kingdom.

Planned enrollment
15th of 17
12 · median 357
Started
2025
with 1 other
Phase 2
Only one
of the 22
Registered
21st of 22
by date
Lead sponsor
1 of 22
Annexin Pharmaceuticals AB

Among the 22 studies in Retinal Vein Occlusion with a site in United Kingdom, this one is the 15th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 2, and was the 21st registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

2 of the 22 studies in Retinal Vein Occlusion with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Retinal Vein Occlusion with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the safety of the investigational medicinal product ANXV. It will also learn about how ANXV works to treat non-proliferative diabetic retinopathy and retinal vein occlusion in adults. The main questions it aims to answer are:

  • Is ANXV safe to use?
  • Does ANXV improve vision or findings related to vision decrease caused by non-proliferative diabetic retinopathy or retinal vein occlusion?
  • Does ANXV lower the number of times participants need to use a rescue medication? Researchers will compare different dose levels of ANXV to see what dose would be be appropriate to test in larger studies.

Participants will:

Take ANXV as a 30 minutes infusion (slow injection) for 5 days. Visit the clinic for checkups and tests at 11 visits during 4 months.

Read the detailed description

The study is an open label, prospective, dose evaluation study to investigate the safety, tolerability and efficacy in patients with Non-Proliferative Diabetic Retinopathy (NPDR) or Retinal Rein Occlusion with recent onset (within 28 days from symptoms onset or diagnosis (whichever is first) to first treatment).

The study consists of 11 visits, whereof one screening visit, five treatment visits and five follow up visits, during a 4 months period.

Intervention is intravenous infusion (30 minutes) with the investigational medicinal product ANXV, a recombinant Annexin A5 protein. The intended dose levels are 4 mg, 1 mg and 6 mg, daily administration for five days.

Safety will be regularly evaluated by the Medical Monitors on a per need basis, as data become available. In case of safety concerns within one indication subset (NPDR and RVO), a lower dose will be initiated within the concerned indication subset (for each subset, independently).

The following assessments will be performed:

Ocular assessments:

  • BCVA
  • OCT and OCTA
  • ERG
  • UWF-retinal imaging
  • UWF-FFA
  • Ocular examination - Slit Lamp biomicroscopy examination, Intraocular Pressure (IOP), RAPD
  • Dilated indirect ophthalmoscopy

Non-ocular assessments:

  • Vital signs
  • ECG
  • Safety labs (blood and urine)
  • Study labs (blood)
03

Conditions studied

  • Non-Proliferative Diabetic Retinopathy
  • Retinal Vein Occlusion

Keywords

  • Annexin A5
  • ANXV
  • Retinal Vein Occlusion
  • Non-Profilerative Diabetic Retinopathy
  • RVO
  • NPDR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in this trial, an individual must meet all the following criteria:

  1. Must have given written (signed and dated), and any authorizations required by local law and be able to comply with all study requirements
  2. Male or female, ≥18 years of age at the time of informed consent
  3. Females should have no according to Clinical Trial Facilitation Group (CTFG) definition.
  4. Clear ocular media and adequate pupillary dilation in the Study Eye to permit high quality retinal imaging
  5. Willing to refrain from unusually strenuous exercise/activity (for example heavy lifting, weight training, intense aerobics classes etc.) for at least 72 hours prior to study visits

    Additionally, NPDR participants must meet the following criteria to be eligible:

  6. Diagnosed with moderately severe or severe non-proliferative Diabetic Retinopathy defined as having a DRSS score of 47 and 53 respectively, and no CI-DMO
  7. Found to have an ETDRS BCVA score in the study eye (SE) of ≥69 ETDRS (equivalent to Snellen 6/12 or 20/40)

    Additionally, RVO participants must meet the following criteria to be eligible:

  8. Diagnosed with Retinal Vein Occlusion with onset of symptoms within 28 days prior to first administration of ANXV

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this trial:

General:

  1. Unwillingness or inability to attend all study visits and/or perform all procedures/tests/examinations, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator
  2. Any major medical or surgical procedure or trauma within 4 weeks prior to the day of trial intervention Treatment 1 (ANXV administration), or planned major surgery within the duration of the study through Day 120
  3. History of any disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study
  4. Prior exposure to a recombinant Annexin A5 protein
  5. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to biologics (for example systemically administered recombinant proteins/peptides; a similar drug class to ANXV)
  6. Uncontrolled hypertension (systolic > 180 mmHg or diastolic > 110 mmHg)
  7. Current use of any systemically administered anti-angiogenic agent (e.g., bevacizumab, sunitinib, cetuximab, sorafenib, pazopanib) or
  8. Diagnosed untreated systemic
  9. A current systemic infection or inflammation that may require antiviral or antimicrobial therapy that will not be completed prior to Screening Visit, or that in the opinion of the Investigator and with concurrence of the Medical Monitor may either put the participant at risk or may influence the results of the study, or the participant's ability to participate in the study
  10. Treatment with another drug, biological agent, or device within 3 months of Screening Visit, or 5 half-lives of investigational agent, whichever is longer or planned participation in an interventional trial from signing Form (ICF) through Day 120
  11. History of thromboembolic events or deep venous thrombosis within 3 months of Screening Visit
  12. Current use of anticoagulant medication (any medications that might have effect on coagulation, haemostasis, and ); low dose aspirin allowed prior to informed consent but must be stopped at the time of consent; may begin again 1 day post Treatment 5 infusion
  13. Current daily use of benzodiazepines
  14. Clinically significant abnormal coagulation parameters at baseline
  15. History of disease with anticipated presence of persistent Annexin A5 antibodies, e.g., antiphospholipid syndrome, systemic lupus erythematosus, rheumatoid arthritis, Behcet disease or systemic sclerosis
  16. Inherited blood disorder (e.g. sickle cell disease, thalassemia)
  17. History of unstable coronary artery disease or cerebrovascular accident within the last 3 months
  18. Current known kidney disease or evidence of kidney disease and below 60 mL/min/1.73m2 at baseline
  19. Current drug or alcohol abuse as per the opinion of the Investigator, or current excessive nicotine intake (e.g. ≥ 20 cigarettes/day, or equivalent, as per the opinion of the Investigator)
  20. Known history of or positive test for chronic infection that affect the immune system (e.g. (HCV), chronic (HBV) and )
  21. Class III obesity ( ≥ 40kg/m2), at the time of informed consent
  22. Within 6 months prior to the Screening Visit, use of medications known to be toxic to the retina, lens, or optic nerve (e.g., deferoxamine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, and ethambutol)
  23. Known hypersensitivity or allergy to fluorescein (e.g., bronchospasm, rash, etc.) or to any component of the study products or a to dilation of the pupil or fixed pupils; mild allergies without angio-oedema or treatment need may be acceptable if deemed not to be of clinical significance (including but not limited to allergy to animals or mild seasonal hay fever)

    Either or both eyes:

  24. A severe (≥0.9 log, Grade 3+ or worse) Relative Afferent Pupillary Defect (RAPD)
  25. An IOP greater than 24 mmHg that is not controlled with medication or surgery at the time of the Screening Visit
  26. Recent (6 months) history of, or presence of uveitis, presence of intraocular inflammation (history of blepharitis is not exclusionary), current ocular infection
  27. Evidence of neovascularization
  28. ETDRS BCVA score in the Fellow eye of ≤54 (equivalent to Snellen 6/24 or 20/80)
  29. Ocular disorders/additional eye disease, which in the opinion of the Investigator may confound interpretation of study results, compromise protocol assessments or are likely to require intervention during the study, including, but not limited to, atrophy of the retinal pigment epithelium, sub-retinal fibrosis, organized hard exudate plaque, retinal detachment, macular hole, vitreomacular traction, macular epiretinal membrane, clinically significant cataract, vitreous opacities or haemorrhage, glaucoma with documented visual field loss, ischemic optic neuropathy, retinitis pigmentosa or choroidal neovascularization of any cause (e.g., AMD, ocular histoplasmosis, toxoplasmosis, or pathologic myopia)
  30. Receipt within the past 6 months or ongoing intravitreal injection of anti-VEGF treatment in either eye

    Study Eye only:

  31. Evidence of deep intraretinal haemorrhage involving the centre 1mm of the macula
  32. Laser photocoagulation in the study eye within the preceding 6 months prior to the Screening Visit, or likely to receive during the study period
  33. Intraocular surgery (including refractive surgery, cataract surgery), or intravitreal (IVT) injection within the preceding 6 months prior to the Screening Visit, or cataract surgery within the preceding 3 months prior to the Screening Visit, or planned intraocular surgery or procedure during the study
  34. Recent (6 months) history, or current evidence of ocular herpetic diseases (including herpes simplex virus, varicella zoster or cytomegalovirus)

    NPDR participants will not be eligible if they meet any of the following criteria (only NPDR participants):

  35. CI-DMO in either eye which, in the opinion of the Investigator, qualifies for anti-VEGF or laser treatment
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    NPDR, 4mg, 5 doses

    ANXV 4mg 30 min infusion

    Biological: ANXV

  • Experimental
    RVO, 4mg, 5 doses

    ANXV 4mg 30 min infusion

    Biological: ANXV

  • Experimental
    NPDR, 6 mg, 5 doses

    ANXV 6mg 30 min infusion

    Biological: ANXV

  • Experimental
    RVO, 4 mg, 3 doses

    ANXV 4mg 30 min infusion

    Biological: ANXV

Interventions

  • BiologicalANXV

    Human Recombinant Protein Annexin A5

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    * Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) * Incidence and titre of anti-drug antibodies (ADA) to ANXV pre- and post-administration

    Time frame: From day 1 to day 120

Secondary outcomes

  1. Anti-drug antibody

    Presence of anti-drug antibodies to ANXV

    Time frame: From day 1 to day 120

  2. Proof of concept

    Efficacy measured by eye functional and anatomical assessments.

    Time frame: From day 1 to day 120

  3. ANXV concentration

    ANXV concentration in blood and urine

    Time frame: From start of administration up to four hours after start of administration, during all treatment days

  4. Rescue medication use

    Number of rescue medication occasions

    Time frame: From day 1 to day 120

Other outcomes

  1. ANXV binding sites

    Amount of ANXV binding sites (phosphatidylserine) in plasma and on erythrocytes

    Time frame: From day 1 to day 120

  2. Cytokine profile

    Cytokine profile in plasma

    Time frame: From day 1 to day 120

  3. ANXV concentration in urine

    ANXV concentration in urine, to evaluate excretion

    Time frame: Four hours after start of treatment, for the third dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD used in a results publication

Supporting information: Study protocol, Clinical study report

Time frame: During the study (as it is an open label study) and during a period after the study that is not yet defined

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2026, 8 months after the start.

Of 14 phase 2 interventional studies under Retinal Vein Occlusion, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 29. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Dec 2, 2025
StartActual
Nov 7, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07259928
Lead sponsor
Annexin Pharmaceuticals AB
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Nov 7, 2025
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Dec 2, 2025

Study contacts

Anna Frostegård
Contact
anna.frostegard@annexinpharma.com
+46701104258
Susan Suchdev
Contact
susan.suchdev@annexinpharma.com
+46702079788
Anna Frostegård, MD, PhD
study director · Annexin Pharmaceuticals AB

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion